Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Endocr Relat Cancer. 2016 Nov 14;24(1):41–52. doi: 10.1530/ERC-16-0402

Figure 1. Gene-sample matrix of mutations on BRAF V600E, RAS and TERT promoter mutations.

Figure 1

The matrix illustrates the genetic status of the 388 cases of papillary thyroid cancer (PTC) included in the present study from the TCGA database. Cases positive for the indicated gene mutations are marked with dark color. Several relationships among the different mutations are evident, including the mutual exclusiveness between BRAF V600E and RAS mutations, the association between BRAF V600E and TERT promoter mutations, and the association between RAS and TERT promoter mutations in PTC. Occurrence of TERT promoter mutation alone is uncommon. Thirty-four of the 39 (87.2%) patients positive for TERT promoter mutations have coexisting either BRAF V600E or RAS mutations and 34/388 (8.76%) of all PTC harbor the genetic duet of coexisting BRAF V600E/RAS and TERT promoter mutations.